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In 2004, the International Agency for Research on Cancer (IARC)
judged that there was sufficient evidence in humans that tobacco
smoking causes cancers of the lung, larynx, oral cavity and
pharynx, paranasal sinuses, oesophagus, stomach, pancreas, liver,
kidney, ureter, bladder, uterine cervix and bone marrow (myeloid
leukaemia; IARC, 2004). At a recent expert review (to be published
as IARC Monograph 100E), the list of cancers for which the
evidence for tobacco smoking being causative was considered to be
‘sufficient’ was updated to include cancers of the colon and
rectum, and mucinous tumours of the ovary (Secretan et al, 2009).
In the 2004 evaluation, the IARC judged that there was sufficient
evidence that involuntary smoking – that is, exposure to second-
hand or ‘environmental’ tobacco smoke (ETS) – causes lung cancer
in humans (IARC, 2004). In this monograph, the results of meta-
analyses were reported, showing a statistically significant and
consistent association between lung cancer risk in spouses of
smokers and exposure to second-hand tobacco smoke from the
spouse who smokes. The relative risk was 1.24 in women and 1.37
in men after controlling for some potential sources of bias and
confounding. The excess risk increases with increasing exposure.
For lung cancer in never smokers exposed to ETS at the workplace,
the relative risks were 1.19 in women and 1.12 in men. For children
exposed to smoke from their parents smoking, the evidence for an
increased risk of lung cancer was less consistent.
The reported increases in risk of lung cancer from ETS exposure
pertain to non-smokers (indeed, usually to persons who have
never smoked). It would be impossible to directly quantify the tiny
increment in risk that a smoker might suffer from exposure to
another person’s smoke (as well as his own). Thus, calculation of
attributable fractions will be undertaken only for lung cancer cases
in never smokers. This makes sense in that the ultimate aim is to
estimate how much cancer is caused by smoking, and this
comprises the cases caused by direct smoking and those caused
by involuntary smoking in never smokers. Even if a theoretical
estimate of the total effect of other persons’ smoking was made
(including the incremental risk to current and past smokers), this
latter component would have to be deducted from the total
tobacco-attributable fraction, as involuntary smoking cannot
occur without active smoking by others.
TOBACCO SMOKING
Methods
The numbers and percentage of cancers caused by tobacco
smoking are estimated using the method developed by Peto
et al (1992). This is based on the assumption that tobacco smoking
is overwhelmingly the most important cause of lung cancer,
and that the incidence of this disease in the absence of smoking
would be more or less the same in all populations, so that
contemporary incidence (or mortality) rates from lung cancer
simply reflect the cumulative exposure of a particular population
to tobacco smoking. A set of data is required for the calculation,
comprising, from the same population, incidence rates of
lung cancer in persons who have never smoked and relative risks
of different cancers in smokers relative to never smokers. Similar
to Peto et al (1992), we use the data from the follow-up during
1982–1988 of the American Cancer Society’s second ‘Cancer
Prevention Study’ (CPS II; Thun et al, 1997), the largest cohort
study carried out until now, involving more than a million
volunteers aged X30 years at the time of enrolment in 1982
(Garfinkel, 1980; Burns et al, 1997). Lung cancer incidence in never
smokers has been estimated from the death rates in the CPS II
study, for a slightly longer period of follow-up (1982–2002; Thun
et al, 2006; Figure 1).
The relative risks of death from different cancers during the
follow-up period (1984–1988); and the sources are shown in
Table 1. Most values listed here were those published in Ezzati
et al (2005). For cancers of the colon and rectum, the values
were those from the follow-up of the CPS II Nutrition Cohort to
June 2005 (Hannan et al, 2009), in which the multivariate hazard
ratios in current smokers were 1.24 in men and 1.30 in women. No
data for the risk of mucinous carcinomas of the ovary in smokers
have been published based on the CPS II cohort; the value used
(2.1) was that from a meta-analysis published by Jordan et al
(2006).
The first step is to calculate the number of lung cancer cases
expected in the UK in the absence of smoking, by applying the age-
and sex-specific never-smoker rates (in Figure 1) to the population
of the UK in 2010. The number of cases attributable to smoking
(and the attributable fraction) is then derived by subtracting the
expected cases from the number actually observed in 2010. The
results are shown in Table 2.
For the other cancers, the rates in non-smokers are not known,
and thus the usual formula for calculating the population *Correspondence: Professor DM Parkin; E-mail: d.m.parkin@qmul.ac.uk
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PAF ¼
Peðr   1Þ
1 þ Peðr   1Þ
where Pe is the prevalence of exposure and r is the relative risk in
smokers.
Using the attributable fractions of lung cancer, already estimated
(Table 2) by age group and sex, and the relative risks for lung
cancer in smokers from the American cohort (Table 1), the above
formula enables calculation of Pe for each age/sex group. This may
be thought of as the ‘notional’ prevalence of smoking (ever vs
never) in the UK population – more specifically, the prevalence
that would have been necessary in the UK population to produce
the observed incidence rates if the relative risks of the CPS II study
had pertained.
Finally, we use the same formula, the values of prevalence (Pe)
and the relative risks for the other cancers (Table 1) to estimate
their PAF and, consequently, the numbers of cases attributable to
smoking.
‘Notional prevalence’ (Pe) is an artificial concept that may be
quite different from the true prevalence, depending on how
different the past experience of tobacco smoking in the population
under study was from that in the volunteers of the CPS II study. It
can, in fact, even be 41 if a particular age/sex/population cohort
has a higher prevalence of smoking and/or a higher relative risk of
lung cancer than the CPS II subjects.
Results
For lung cancer (Table 2), the results suggest that about 85% of the
lung cancer cases in men are attributable to smoking, and in
women the percentage is 80%.
Table 3 shows the estimated numbers of cancer cases at sites
other than the lung, and the fractions due to tobacco smoking. (No
estimate is made for cancers of the paranasal sinuses, owing to the
lack of relevant data on the risk of tobacco smoking; the number of
cases concerned would be very few: the total number of cases
registered in England in 2008 was 125.)
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Figure 1 Age-specific incidence rates of lung cancer in the lifelong never
smokers (CPS-II) in the US.
Table 1 Estimated relative risks (RR) for current smokers aged X35
compared with never-smokers
Cancer Male Female
Lung
a 21.3 12.5
Oral cavity and pharynx
b 10.9 5.1
Oesophagus
b 6.8 7.8
Stomach
a 2.2 1.5
Liver
a 2.3 1.5
Pancreas
a 2.2 2.2
Colon–rectum
c 1.24 1.30
Larynx
b 14.6 13.0
Cervix
a — 1.5
Ovary (mucinous)
d — 2.1
Urinary bladder
a 3.0 2.4
Kidney and renal pelvis
a 2.5 1.5
Acute myeloid leukaemia
a 1.9 1.2
aFrom Ezzati et al (2005).
bFrom US Department of Health and Human Services
(2004).
cFrom Hannan et al (2009).
dFrom Jordan et al (2006).
Table 2 Cases of lung cancer attributable to smoking, by sex and age group (UK, 2010)
Age group
(years)
Population
(thousands)
Rates
observed
Cases
observed
Rates
expected
a
Cases
expected
a
Excess
attributable cases PAF (%)
Males
0–14 5548 0.0 1 0.0 0 1 0
15–34 8365 0.5 38 0.5 38 0 0
35–44 4387 4.9 215 2.9 128 87 40
45–54 4202 27.1 1138 6.0 252 886 78
55–64 3580 116.9 4184 14.3 513 3705 89
X65 4526 368.9 16697 51.5 2331 14366 86
Total 30609 72.8 22273 — 3262 19011 85
Females
0–14 5292 0.0 2 0.0 0 2 0
15–34 8048 0.4 42 0.5 42 0 0
35–44 4452 4.5 224 3.8 168 56 25
45–54 4331 26.7 1088 7.4 320 768 71
55–64 3731 85.3 3441 14.9 556 2885 84
X65 5759 218.0 13335 42.9 2471 10864 81
Total 31614 53.1 18132 — 3557 14575 80
Abbreviations: PAF¼population-attributable fraction.
aExpected in a population that had never smoked.
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36102 (22.8% of the total) cancers in men and 23722 (15.2% of the
total) in women are attributable to smoking tobacco (currently, or
in the past).
Discussion
The method of estimation developed by Peto et al (1992, 2000) is
based on the assumption that the excess mortality (or incidence)
from lung cancer, above that which would have been observed in
persons who have never smoked, is the result of smoking (past and
current). Thus, the attributable fraction of lung cancer can be
estimated as
ðcasesobserved   casesexpectedÞ=casesobserved
and used to estimate the attributable fractions of other cancers. It
should be noted that it is of no consequence that the data set used for
estimates of PAF in 2010 is derived from study results pertaining to
the period 1984–1988, so long as the two components (mortality/
incidence of lung cancer in non-smokers, and relative risks of
different cancers in smokers vs never-smokers) derive from the same
population. On the other hand, it is important that the non-smoker
rates observed in the US volunteers in 1984–1988 are appropriate to
the UK population in 2010. The only large cohort study in the UK
was for British Doctors – almost all of them being men. The US CPS
II non-smoker rates predicted 19.03 lung cancer deaths in 40 years of
follow-up, vs 19 actually observed (Peto et al, 2000), confirming that
non-smoker rates in the UK are likely to be very similar to those in
the US CPS II cohort.
The main advantage of the Peto method is that it does not
require detailed information of the current relative risks of
different cancers in relation to smoking history in the UK
population. The risk of tobacco smoking depends on cumulative
exposure to carcinogens in tobacco smoke, and therefore varies
with the amount smoked, duration of smoking and time since
cessation (in ex-smokers), as well as with the type of cigarette
smoked. Factors such as these differ between countries, and over
time, and thus one cannot be sure that relative risks taken from
studies in different populations (geographic or temporal) would be
appropriate for the UK in 2010. In the USA, the relative risk of lung
cancer in current smokers (relative to never smokers) was 11.5 in
men and 2.7 in women in the Cancer Prevention Study I (CPS I)
conducted by the American Cancer Society during 1959–1965,
whereas it was 23.3 in men and 12.7 in women in CPS II (US
Department of Health and Human Services, 2004). In the British
Doctors study, the relative risk in current smokers rose from 15.5
during 1951–1971 to 18.5 during 1971–1991 (Doll et al, 1994). In
fact, one might have expected the switch to cigarettes delivering
low tar to have reduced the hazard of lung cancer, but this effect is
being offset by the ‘maturing’ of the smoking epidemic, and thus
smokers still alive in more recent years have had a longer history
of regular consumption of cigarettes than men of the same ages
would have had during the 1950s and 1960s. Another factor that
may be important in the maturing of the epidemic (but which is
impossible to quantify) is a change in the way cigarettes have been
smoked in recent decades. The minority of doctors who continued
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Table 4 Relative risks of lung cancer from exposure to ETS (IARC, 2004)
RR by sex
Source of exposure to ETS Males Females
At home (spouse) 1.37 1.24
At work (occupational) 1.12 1.19
Abbreviations: ETS¼environmental tobacco smoke; RR¼relative risk.
Cancer, lifestyle and environment in the UK in 2010
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to be those who smoked them in a way different from that of the
greater number who had stopped smoking them earlier.
Using the ratio of mortality rates from lung cancer in never,
former and current smokers after the 50-year follow-up of British
doctors (Doll et al, 2005), and the prevalence of smoking among
British men in 2008 (22% current smokers, 30% ex-smokers;
General Lifestyle Survey 2008/ONS 2010, 2010), the estimate of the
PAF of lung cancer is 80%. This is somewhat lower than the 85%
estimate of the current analysis, and that of Peto et al (2006), who,
using essentially the same methodology, estimated that 88% of
lung cancer deaths in men in the UK in the year 2007 were due to
smoking, and 84% of deaths in women. The reason, as noted
above, is that the relative risks observed in British doctors are
unlikely to be the same as the averages for the UK population
in 2010.
ENVIRONMENTAL TOBACCO SMOKE (ETS)
Methods
Estimation of the fraction of cancer caused by exposure to ETS in
lifelong non-smokers uses the traditional method for attributable
fractions, incorporating estimates of relative risk (of exposure to
tobacco smoke) and the prevalence of such exposure among never
smokers. The formula for calculating PAF is as follows:
PAF ¼
Peðr   1Þ
1 þ Peðr   1Þ
where Pe is the prevalence of exposure and r is the relative risk of
lung cancer in those exposed to ETS. The attributable fraction is
applied to the number of lung cancer cases estimated to occur
among never smokers. From the section on tobacco smoking, this
was estimated to be 6819 (3262 in men and 3557 in women) in the
UK in 2010 (Table 2).
We may estimate two components:
(1) Cases of lung cancer (in never smokers) caused by domestic
exposure to ETS.
(2) Cases of lung cancer (in never smokers) caused by exposure to
ETS in the workplace.
The relative risks from the IARC (2004) meta-analyses, described
in the Introduction, are used (Table 4).
Exposure to ETS at home Most studies investigate the risk of
lung cancer in lifelong non-smokers (never-smokers) living with a
smoking spouse, and it was on a meta-analysis of such studies that
the estimated relative risks in the IARC monograph were based.
There appear to be no survey data upon which one can estimate
the prevalence of such exposures in the UK. A range of approaches
have been used by others, from using the exposure prevalence of
control subjects in case–control studies (IARC, 2007) to extra-
polation from exposure of children to ETS at home (Jamrozik,
2005). Tre ´daniel et al (1997) estimate the exposure from spouse
smoking based on the prevalence of smoking in men and women,
and the probability that couples would be discordant for their
smoking status. This seems to be the method most likely to yield
exposures equivalent to those for which relative risks have been
estimated, as well as allowing estimates specific to the UK (which
controls from case–control studies cannot). Using data from the
General Household Survey for 2008, we may obtain the prevalence
of current, ever or never smokers by age group, as well as the
probability of being married or cohabiting currently or ever in the
past. We use the ‘aggregation factor’ of 3.0 proposed by Wald et al
(1986) to express the relative probability of couples being
concordant for smoking status.
Table 5 shows the percentage of the UK population who are
currently married or cohabiting (column 1), and the percentage
Table 5 Prevalence estimates of cohabitation with smoking partner among non-smokers in UK, and fraction of lung cancer cases attributable to
cohabitation with a smoking partner
Cohabitation status
of never-smokers
(%)
a
Population
smoking status
(%)
a
Estimated prevalence of never-smokers cohabiting with
smoking partner and lung cancer cases attributable to
cohabitation with smoking partner (%)
b
12 3 4 5 67891 0
Age group
(years)
Living with
a partner
Ever had
a partner
Current
smokers
Never
smokers
Never-smokers
living with current
smoking partner PAF
Never-smokers
living with ever
smoking partner PAF
Never-smokers
ever living with
smoking partner PAF
Men
16–24 8 8 24 69 1 0.5 2 0.6 2 0.6
25–34 61 63 30 53 10 3.5 19 6.4 19 6.6
35–44 77 82 24 51 11 3.8 25 8.3 26 8.8
45–54 77 88 24 48 11 3.8 24 8.1 27 9.1
55–64 79 93 18 41 7 2.5 16 5.6 19 6.5
65–74 77 94 13 37 4 1.3 20 6.9 25 8.3
X75 60 93 13 37 8 2.8 14 5.0 22 7.5
Total 63 72 22 49 6 2.0 17 6.0 20 6.8
Women
16–24 18 19 26 71 3 1.0 4 1.5 4 1.5
25–34 68 72 29 57 12 4.1 24 8.1 25 8.6
35–44 75 87 25 56 8 3.0 29 9.8 34 11.2
45–54 75 93 24 57 10 3.4 31 10.3 38 12.4
55–64 72 96 22 55 4 1.6 29 9.7 39 12.5
65–74 63 96 13 56 7 2.5 32 10.7 50 15.5
X75 29 94 13 56 4 1.6 14 5.1 47 14.8
Total 59 79 21 57 7 2.5 23 7.8 31 10.1
Abbreviations: PAF¼population-attributable fraction.
aCohabitation status and population smoking status from General Lifestyle Survey 2008/ONS 2010 (2010).
bEstimates are
based on cohabitation status and population smoking status, and assume couples are in the same broad age groups as those in the table and the relative probability of couples
being concordant for smoking status is 3.0 (Wald et al, 1986).
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group. Column 3 shows the prevalence of current smokers, and
column 4 the percentage of persons who have never smoked.
Under the assumption that couples are in the same broad age
groups as those in the table, and that the ‘aggregation factor’
described above is 3.0, we can estimate the percentage of never
smokers who belong to the following categories:
  Currently living with a smoking partner (column 5)
  Currently living with a partner who has ever smoked (column 7)
  Has ever lived with a partner who was a smoker at some point of
time (column 9).
The corresponding attributable fractions of lung cancers among
never smokers are shown in columns 6, 8 and 10. They range from
2% of lung cancer cases in non-smoking men (due to their current
partner’s smoke) to 10.1% of lung cancers in non-smoking women,
as a consequence of ever having had a partner who was a smoker at
some point of time.
Although the relative risks derive from studies of non-smokers
with current partners who smoked, the corresponding estimates of
PAF in Table 5 (column 6) are probably an underestimate, because
of the following factors:
  They take account only of current partnerships, and it is likely
that past partnerships with a smoker would have had some
adverse effects, particularly when separation had occurred only
recently
  Some non-smoking partners may have quit relatively recently,
and their past smoking would have had an adverse effect
  There may be other members of the household smoking, even
though the partner does not.
For these reasons, the attributable fractions in column 8 (based on
non-smokers with a current partner who was ever a smoker) are
taken as the relevant estimate for the UK population.
Exposure to ETS at work Jamrozik (2005) gives the prevalence
of passive smoking at work as 11%, an estimate that probably
derives from the survey commissioned by ASH in April 1999,
which revealed that approximately 3 million people in the UK are
regularly exposed to ETS at work (ASH, 2004). There are otherwise
very few data on workplace exposure to ETS in the UK. Chen et al
(2001), in a small sample derived from participants in the fourth
Scottish MONICA survey of 1995, found that any (regular)
exposure of adults aged 25–64 years to environmental tobacco
smoke at work was 68.1% for men and 57.5% for women (of which
21.5% of men and 17.4% of women classified such exposure as
‘some’ or ‘a lot’). The EPIC study collected data on exposure to
ETS at the time of recruitment among 123000 non-smokers from
11 centres (none of them in UK) during 1993–1998, 78% of whom
were women; 67% reported exposure at work (Vineis et al, 2005).
The proportion of non-smoker controls in the multi-centre
Table 6 Lung cancer cases attributable to exposure of non-smokers to ETS in UK in 2010
Source of exposure
Both
Spouse Workplace Independent ETS exposure Correlated ETS exposure
Age group
(years) PAF Obs.
Excess
attributable cases PAF Obs.
Excess
attributable cases Obs.
Excess
attributable cases PAF (%)
Excess
attributable cases PAF (%)
Men
16–24 0.01 0 0 0.08 0 0 0 0 — 0 —
25–34 0.06 38 2 0.08 38 3 38 5 13.7 5 12.9
35–44 0.08 128 11 0.08 128 10 128 20 15.5 19 14.6
45–54 0.08 252 20 0.08 252 20 252 38 15.3 36 14.4
55–64 0.06 513 28 0.08 513 40 513 66 12.9 62 12.0
65–74 0.07 854 59 0.08 854 67 854 121 14.2 114 13.3
X75 0.05 1478 74 0.08 1478 115 1478 183 12.4 170 11.5
All ages 3262 195 3262 255 3262 434 — 406 —
% of total (all ages) 6.0 7.8 13.3 12.4
Women
16–24 0.01 0 0 0.09 0 0 0 0 0
25–34 0.08 42 3 0.09 42 4 42 7 16.5 7 15.6
35–44 0.10 168 16 0.09 168 15 168 30 18.0 29 17.1
45–54 0.10 320 33 0.09 320 29 320 59 18.5 56 17.6
55–64 0.10 556 54 0.09 556 51 556 100 18.0 95 17.1
65–74 0.11 822 88 0.09 822 75 822 155 18.9 148 18.0
X75 0.05 1649 84 0.09 1649 151 1649 227 13.8 212 12.8
All ages 3557 279 3557 325 3557 578 — 547 —
% of total (all ages) 7.8 9.1 16.3 15.4
Persons
16–24 0 0 0 0 0 0 0
25–34 80 6 80 7 80 12 15.2 6 7.3
35–44 296 27 296 25 296 50 16.9 27 9.1
45–54 572 53 572 49 572 98 17.1 53 9.3
55–64 1069 82 1069 91 1069 166 15.5 82 7.7
65–74 1676 147 1676 142 1676 276 16.5 147 8.8
X75 3127 158 3127 266 3127 410 13.1 158 5.0
All ages 6820 474 6820 580 6820 1013 — 952 —
% of total (all ages) 6.9 8.5 14.8 14.0
Abbreviations: ETS¼environmental tobacco smoke; Obs.¼observed cases; PAF¼population-attributable fraction.
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ever being exposed to ETS at work was 71% in men and 47% in
women.
It is difficult, based on such incomplete data, and the varying
definition of ‘exposure’, to decide an appropriate prevalence for
the UK. On the basis of the average of the results from Boffetta
et al (1998), Chen et al (2001) and Vineis et al (2005), 71% for men
and 53% for women, 8% of lung cancers in never-smoking men
and 9% in women would be due to workplace exposure to ETS.
With the much lower exposure estimate of Jamrozik (11%), the
attributable fractions would be 1.3% and 2.0% in men and women,
respectively.
RESULTS
Estimate of attributable fraction in lifelong non-smokers
Table 6 shows the final estimates of lung cancer attributable to ETS
from the spouse, and at work, with the assumptions described
above. With respect to combined exposure, it is assumed that the
relative risks are simply multiplicative (no interaction). The
exposures are assumed to be either
  independent of each other or
  correlated, in that individuals exposed at home are more likely
to be exposed at work. In fact, the concordance between
exposures at the two sites is rather weak: on the basis of the
results among the control subjects in the study by Boffetta et al
(1998), the k value is  0.005 for women and þ0.05 for men.
In total, 14–15% of lung cancer cases among individuals who
have never smoked are estimated to be due to exposure to ETS.
DISCUSSION
The estimate of the effect of exposure to spousal smoking is based
on current (2008) data on the proportion of persons married or
cohabiting, and an estimate of the likelihood that their current
partner has ever smoked. The percentages are 17% for men (aged
over 16) and 23% for women. Self-reported exposure to spousal
smoke among controls in the multi-centre European case–control
study of Boffetta et al (1998) was reported as 12.8% for men and
62.7% for women – but these are values for those ever exposed,
which were used in estimating the PAF in France (IARC, 2007). In
the EPIC study, 28.5% of non-smokers (78% women) from 11
centres in Europe (not UK) reported ETS exposure (probably at
the time of recruitment) at home (Vineis et al, 2005). The estimates
of Jamrozik (2005)   37% of adults under 65 exposed at home –
are clearly inappropriate, as they relate to exposure of children to
smoke at home from either parent. In the UK, Jarvis et al (2003), in
a sample of adults from the general population of England in 1994
and 1996, found that among 9556 married or cohabiting non-
smokers 14.5% had a partner who was a current cigarette smoker.
This is similar to the indirect estimate of 17% (men) and 23%
(women) who would be expected to have a smoking partner, based
on the current prevalence in 2008, and an aggregation factor of 3,
on which the result in Table 5 is based. Smoking prevalence has
declined over time, and exposure to smoke from a smoking spouse
would have been greater in the past (among individuals developing
lung cancer in 2010), especially for women, as smoking has
declined among men much more than among women. However, as
the estimate is based on the probability of the current partner ever
having been a smoker, any bias will be small.
The estimate of the role of exposure to ETS in the workplace
uses the relative risks from the meta-analysis of case–control
studies conducted by IARC (2004). A somewhat more recent meta-
analysis of 22 studies (Stayner et al, 2007) suggested a similar
magnitude of relative risk (1.24). The definition of ‘exposure’ in
the studies included in these analyses varies, and, in any case,
estimates of the PAF depend on the prevalence of workplace
exposure to ETS in the UK population, for which there are no
representative data.
A previous estimate for deaths attributable to passive smoking
in the UK was made by Jamrozik (2005). The results are rather
different from those obtained here – 1372 deaths from lung cancer
due to exposure at home and 160 due to exposure at work. The
Table 7 Cases of lung cancer attributable to tobacco, by sex and age group (UK 2010)
Total attributable cases
Age group (years) Observed cases Smoking attributable cases ETS attributable cases Excess attributable cases PAF (%)
Males
0–34 38 0 5 5 14
35–44 215 87 20 107 50
45–54 1138 886 38 924 81
55–64 4184 3671 66 3737 89
X65 16697 14366 305 14671 88
Total 22273 19011 434 19445 87
Females
0–34 42 0 7 7 17
35–44 224 56 30 86 39
45–54 1088 768 59 827 76
55–64 3441 2885 100 2985 87
X65 13335 10864 382 11246 84
Total 18132 14575 578 15153 84
Persons
0–34 80 0 12 12 15
35–44 439 143 50 193 44
45–54 2226 1654 98 1752 79
55–64 7625 6556 166 6722 88
X65 30032 25230 687 25917 86
Total 40405 33586 1013 34599 86
Abbreviations: ETS¼environmental tobacco smoke; PAF¼population-attributable fraction.
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of exposure (as mentioned above) and relative risk, and the
attribution of no lung cancer deaths after the age of 64 years to
workplace exposures. What is more, Jamrozik estimates lung
cancer deaths attributable to passive smoking in the whole
population – including among current and past smokers; as noted
in the introduction, this is illogical, as such deaths would not occur
among non-smokers if no one smoked.
SUMMARY
Table 7 summarizes the findings with respect to lung cancer and
exposure to tobacco smoke. In total, 34599 cases of lung cancer in
the UK (86% of the total) were due to exposure to tobacco smoke
in 2010, the great majority of which (97.4%) are due to active
smoking (current or in the past). The figures for men are 87%
cases due to exposure to tobacco (of which 97.7% were due to
smoking), and for women 84% cases due to exposure to tobacco
(of which 96.2% were due to smoking).
Table 8 shows the final summary of the estimate of tobacco-
attributable cancer in the UK. In total, the estimate is of 60837
cancer cases (19.4% of all new cancer cases) attributable to
tobacco: 36537 (23.0%) of cancers in men and 24300 (15.6%) of
cancers in women.
See acknowledgements on page Si.
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Table 8 Cancer cases caused by exposure to tobacco smoke (by smoking, or environmental), UK 2010
Cases in UK, 2010
Cancer Observed cases
Excess attributable cases
Number (% at this site)
Population-attributable fraction
(% of all cancers)
Males
Lung 22273 19445 (87) 12.3
Oral cavity and pharynx 4573 3180 (70) 2.0
Oesophagus 5711 3574 (63) 2.3
Stomach 4467 1167 (26) 0.7
Liver 2270 620 (27) 0.4
Pancreas 4082 1071 (26) 0.7
Colon–rectum 22125 1469 (7) 0.9
Larynx 1802 1424 (79) 0.9
Cervix uteri — — —
Ovary — — —
Bladder 6711 2520 (38) 1.6
Kidney 5697 1677 (29) 1.1
Leukaemia 4639 390 (8) 0.2
All cancers 158667 36537 (23.0) 23.0
Females
Lung 18132 15153 (84) 9.7
Oral cavity and pharynx 2355 1292 (55) 0.8
Oesophagus 2817 2009 (71) 1.3
Stomach 2576 398 (15) 0.3
Liver 1298 199 (15) 0.1
Pancreas 4280 1325 (31) 0.9
Colon–rectum 17786 1766 (10) 1.1
Larynx 382 302 (79) 0.2
Cervix uteri 2693 195 (7) 0.1
Ovary 6820 177 (3) 0.1
Bladder 2571 883 (34) 0.6
Kidney 3364 504 (15) 0.3
Leukaemia 3201 96 (3) 0.1
All cancers 155584 24300 (15.6) 15.6
Persons
Lung 40405 34599 (86) 11.0
Oral cavity and pharynx 6928 4472 (65) 1.4
Oesophagus 8528 5583 (65) 1.8
Stomach 7043 1565 (22) 0.5
Liver 3568 819 (23) 0.3
Pancreas 8362 2396 (29) 0.8
Colon–rectum 39911 3235 (8) 1.0
Larynx 2184 1726 (79) 0.5
Cervix uteri 2693 195 (7) 0.1
Ovary 6820 177 (3) 0.1
Bladder 9282 3403 (37) 1.1
Kidney 9061 2181 (24) 0.7
Leukaemia 7840 487 (6) 0.2
All cancers 314251 60837 (19.4) 19.4
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